FINWIRES · TerminalLIVE
FINWIRES

$ELAN

5 stories mentioning ELANUpdated 37d ago

Every FINWIRES story that references ELAN, newest first.

What are analysts saying about ELAN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ELAN?

Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Neurocrine Biosciences (NBIX) shares gained 2.5% after the company said Friday it has started a phase 1 first-in-human trial of NBIP-1968, an experimental drug for obesity.ANI Pharmaceuticals (ANIP) shares were down 6.2% even after it posted higher Q2 adjusted earnings and net revenue.The US Food and Drug Administration said Friday it issued an emergency use authorization for Elanco Animal Health's (ELAN) CLiK Extra wound spray to prevent New World screwworm infestations in sheep, cattle, goats, swine and several other animal species. Elanco shares were down past 5%.

$ANIP$ELAN$NBIX
Wire

Elanco's CLiK Extra Gets FDA Emergency Use Authorization for New World Screwworm

The US Food and Drug Administration said Friday it issued an emergency use authorization for Elanco Animal Health's (ELAN) CLiK Extra wound spray to prevent New World screwworm infestations in sheep, cattle, goats, swine and several other animal species.The emergency use authorization permits the use of CLiK Extra only for the prevention of New World screwworm myiasis associated with wounds, birth, and surgical or husbandry procedures.The wound spray is not approved or conditionally approved by the FDA for any indication, according to the regulator.Price: $23.54, Change: $-0.66, Percent Change: -2.73%

$ELAN
Wire

UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating

Elanco Animal Health (ELAN) has an average rating of buy and mean price target of $31.46, according to analysts polled by FactSet.Price: $24.19, Change: $-2.03, Percent Change: -7.74%

$ELAN
Wire

Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says

Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories (IDXX) appearing to be "more de-risked than compelling" and Zoetis (ZTS) looking safe rather than having a high upside, UBS said in its animal health preview note Monday.Elanco's accelerating momentum in US pet health segment through May, along with its Credelio Quattro product share gains, support a revenue beat for the quarter and guidance raise, UBS analysts said. They added that solid Q2 results, an increase in revenue for its innovation segment, and a positive outlook for H2 should drive up shares.For IDEXX, a recurring revenue beat in its companion animal group segment and an increase in placements for inVue product should help drive good results, the analysts said. They stated that stabilization of vet visits plus a clearer product catalyst at the company's Aug. 13 investor day would help boost sentiment on the stock further.Zoetis looks to have a limited downside currently, but for "meaningful" upside, the company needs a "cleaner" Q2 beat, a guidance reset that inspires more confidence, and more clarity on the pipeline in the next two years, the analysts said.UBS kept Elanco's stock rating at buy and price target at $31, maintained IDEXX's stock rating at neutral and cut its price target to $620 from $640, and reiterated Zoetis' stock rating at neutral and reduced its price target to $85 from $99.Price: $25.33, Change: $+0.41, Percent Change: +1.67%

$ELAN$IDXX$ZTS
Pet Industry Bitten by Inflation May Make Attractive Takeover Targets
US Markets

Pet Industry Bitten by Inflation May Make Attractive Takeover Targets

Rising prices and reduced affordability are leading to declining pet ownership, taking a bite out of industry valuations and potentially signaling a coming wave of consolidation, according to equity analysts.The share of US households with a pet has declined in the past two years by about 2.6%, and dog adoptions have fallen, according to Bank of America research. The cost of veterinary care has also risen, adding to pet owners' concerns."It's clear that people still love their pets, but the cost associated with owning a pet is increasingly shaping household budgeting decisions, and we see that really clearly in our data," Taylor Bowley, the Bank of America Institute economist who wrote the research note, said in an interview with. "Ownership every day is getting more expensive."Shares of Chewy (CHWY) and Trupanion (TRUP) are both down about 50% in the past year, and Bark (BARK) is off by 43%. PetMed Express (PETS) is down 41%, Freshpet (FRPT) has lost 22%, and Petco Health and Wellness (WOOF) has dropped 7.8%.Decreased valuations will likely make pet companies, which have recently become e-commerce companies as more consumers buy food and supplies for their furry friends online, attractive targets for companies seeking acquisitions in the segment.Bank of America equity analyst Michael McGovern said that while it's hard to predict M&A activity, the share price drop across the pet sector within the e-commerce industry is notable."These are some of the most attractive valuations that we've seen across recent - call it 10 years - for the e-commerce sector specifically," he said in an interview.Recent M&A activity in the pet sector includes two deals by Chewy in the animal health area - an April offer to acquire Modern Animal to expand its veterinary care services and a deal from October 2025 for SmartPak Equine, which is an online seller of horse supplies and supplements. In February, Elanco bought AHV International BV for $380 million to expand its business in the Netherlands.Freshpet is a long-term acquisition candidate, Oppenheimer analyst Rupesh Parikh said in a March report. The maker of refrigerated cat and dog food didn't respond immediately to an email seeking comment.Pet food manufacturers and retailers have shown a growing interest in the fresh pet food category. Freshpet's leading product portfolio and position in the fresh segment are making it an attractive target, and the stock has "downside support" precisely because of its takeout potential, Parikh said.M&A in the pet segment, as with most other sectors, comes with certain risks for not just industry players but also consumers. That can be seen in consolidation in the veterinary services industry, Bank of America said. About 25% to 30% of US veterinary practices, which represent roughly three-fourths of all specialty clinics, are now owned by large corporations or private equity firms. That's drawn the attention of some members of Congress."Such consolidation can erode competition, elevate prices, and weaken service quality, ultimately reducing consumer choice," BofA economist Bowley said in the note.Still, not everybody is convinced that the pet sector is seeing any sort of downturn.Jeff Simmons, the chief executive at Elanco Animal Health (ELAN), said the company has researched pet health spending that shows no decline."The resiliency and the willingness to spend on pet health, maybe not toys or premium dog food, but on pet health, is actually the same or increasing during these economic times," Simmons said in an interview with.Only 5.2% of pet owners in a TD Cowen survey conducted in May said they plan to spend less on pets, pet products, or veterinary services in the next six months, down from 5.4% in January. More than half - 55% -- said they expect spending to be unchanged, and 40% will spend more.Shares of Elanco doubled last year and are up 9% year to date as of June 26."We're seeing a durability at a time of a consumer pullback on a lot of stuff," Simmons said. "We're not seeing it in our industry, and I will tell you, we're not seeing it in our results."Morgan Stanley analysts said in a recent note that the pet industry will remain in neutral amid inflation that drives ownership costs higher."The pet industry is entering a more mature growth phase after COVID-related outperformance and a subsequent inflationary period, which has continued to date," the analysts said in a May 29 note to investors.The Bank of America note showed that spending on pets dropped the most among lower-income households and younger pet owners. If prices continue to rise, veterinarians will likely have to rely on repeat visitors to offset economic trends."If current macro headwinds persist, veterinary pricing will become increasingly harder for everyday pet owners to absorb, accelerating pressure on visit volumes through deferred care," the bank said.Matthew LeisingPrice: $24.71, Change: $+0.62, Percent Change: +2.57%

$ELAN

Track with the FINWIRES app suite